I recently ran down some of the positive developments for U.S. weed investors coming out of Washington, D.C. – developments that can, and should, be seen as powerful profit catalysts for pot stocks, because they all helped push this segment higher in April.
But if you think things are looking up in the United States, just wait until you see what’s happening up north of the border, in Canada, where the entire country is expected to take medicinal and recreational weed fully legal in just a few weeks’ time, in July.
Why is this Canadian law great news for American investors?
It’s simple: Canadian cannabis companies, which any American investor can easily own, have the potential to explode – particularly the five tiny Canadian pot stocks in my Nova-X Report Roadmap to Marijuana Millions model portfolio.
To help fill in my readers on just how monumentally profitable these changes north of the border are going to be, I sought out the leader of one of Canada’s top cannabis companies.
He’s a brilliant businessman and newly appointed head of the Cannabis Canada Council.
And every weed investor should hear what he has to say…
Here’s What Happened When I Talked with a Cannabis Giant
Late last week, I got a chance to sit down and chat with Dr. Avtar Dhillon about the state of the Canadian cannabis industry – and its future. That’s a subject Dr. Dhillon knows well. Besides helping to found and lead one of Canada’s most important medical cannabis cultivators and researchers, he also is the newly appointed board chair of the Cannabis Canada Council, a new, nationwide industry association.
Lately in his new position, Dr. Dhillon has been hosting business and government officials from around the world, and they’re all interested in seeing how Canada is setting up its cannabis industry ahead of full medical and recreational legalization later this summer.
RELATED: Top five tiny Canadian pot stocks are set to skyrocket. Click here…
Dr. Dhillon tells me the run-up to nationwide legalization has given Canada’s pot companies a chance to get settled ahead of the competition in the United States and elsewhere. This gives them a tremendous growth opportunity, as they’re setting up deals internationally as other countries legalize marijuana.
The global medical cannabis market alone is expected to reach $55.8 billion by 2025, according to Grand View Research.
“There’s a lot of money out there that has not had a chance to partake in where this industry is going,” Dr. Dhillon says. “It’s not too late. One of the lowest-hanging fruits is going to Canada for established, public entities that have gone through regulatory scrutiny.”
I couldn’t agree more. It’s why I keep including Canadian firms in the model pot stock portfolio of recommendations I make for my paid-up Nova-X Report subscribers.
While our conversation was wide ranging, I got down to the nitty-gritty. It’s been a rough first quarter for pot stock investors, although April was quite a bit better – and so I grilled Dr. Dhillon about his industry’s near-term prospects.
He didn’t blink. While Dr. Dhillon knows investors aren’t happy about cannabis companies’ sharp drop early this year, he was quick to point out three big catalysts that will lead to soaring pot company profits – and share prices.
Here’s what he had to say…
Pot Stock Catalyst No. 1: Full Legalization Up North
When the Senate of Canada votes on the medical and recreational cannabis legalization bill June 7, it’ll be the first industrialized nation to fully legalize marijuana.
The vote itself is considered a done deal at this point, meaning the real fireworks will launch later in the summer – probably in August, when legal recreational cannabis finally goes on sale.
Pot Profits: Forget Jeff Sessions! These Five Canadian Pot Stocks Are Set to Skyrocket. Click Here…
Canada is the second-largest single market for legal cannabis in North America behind California, according to Arcview Market Research and BDP Analytics.
Canada’s total legal weed market, when recreational use is legalized and regulated, soon could reach $22.6 billion, a Deloitte study notes.
“Legalization is one of the greatest opportunities in the world at this point and in the foreseeable future,” Dr. Dhillon says.
Pot Stock Catalyst No. 2: Big Moves in Washington
Political and legal reform in the United States is another big catalyst that Dr. Dhillon is excited about.
And it’s something we’ve been following here.
Last week, we talked about how U.S. President Donald Trump and U.S. Sen. Cory Gardner (R-CO) have come to an agreement to end federal-level crackdowns on marijuana in legalized states.
Moreover, legislators from both political parties are collaborating to keep the feds hands-off, to legalize industrial hemp, and to license banks to handle the billions generated by legal cannabis sales.
And that’s not even including the fact that citizens in a host of states are set to vote on legalization bills this fall.
About 63% of U.S. voters now support fully legalizing marijuana, according to the latest poll by Quinnipiac University. Support for medical marijuana is effectively universal – 93% of those polled approve.
“The key thing in my mind is when, in the U.S., growers can grow and sell pot and put the money into a national bank,” Dr. Dhillon said. “That’s when the big money is going to come in.”
We also talked about another interesting aspect of cannabis policy, particularly here in the United States. It’s not exactly a profit catalyst – yet – but it really speaks to the tremendous potential here.
Cannabis Could End the Opioid Crisis
This past weekend, I caught up on “Weed 2: Cannabis Madness.” That’s a CNN special report, which first aired March 11, reported by Dr. Sanjay Gupta about the opioid epidemic and treating addicted patients with medical cannabis.
Opioids killed more Americans in 2016 than breast cancer, and Dr. Gupta highlighted instances where medical marijuana might provide some relief for addicts, as well as the need to conduct medical research on the plant.
That’s not going to happen on any realistic scale until the U.S. Drug Enforcement Agency changes pot’s classification to allow for more research on the plant to take place.
I mention CNN‘s report because it was Dr. Gupta who changed Dr. Dhillon’s mind about medical marijuana.
Dr. Dhillon practiced medicine for 12 years before becoming a businessman and the highly successful CEO of Inovio Pharmaceuticals Inc. (Nasdaq: INO).
A marijuana skeptic at the time, Dr. Dhillon watched CNN‘s 2013 documentary “Weed,” also reported by Dr. Gupta, which helped convince him of medical marijuana’s benefits.
These days, Dr. Dhillon is supportive of decriminalizing cannabis for recreational use, too, and bringing rigorous, consistent quality standards to pot products on the market.
“It’s a very exciting time,” he tells me.
When Canada Takes Weed Fully Legal…
…It’ll probably make our retrograde attorney general hopping mad, but there’s really nothing on Earth he can do to stop these small cannabis companies from hitting the stratosphere. Sessions could be furious, but folks who park a few hundred dollars into these “north of the border” firms could potentially turn a small stake into $100,000 – and fast. Michael Robinson has the details for you – click here to hear what he’s got to say…
About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience – for free. Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.To get full access to all Money Morning content, click here.
Disclaimer: © 2018 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201.